Stanford University researchers said hospital use of recombinant factor 7a, an expensive hemophilia drug, increased 140 times in 2008 compared with 2000. Off-label use, such as during heart surgery or treating trauma, made up most of the increase. The drug was used in patients with hemophilia 4% of the time, according to a study published in Annals of Internal Medicine. Off-label use can increase the risk of heart attack and stroke because it raises blood-clot risk, the researchers said.
Published in Brief: